NDAVAGINALOINTMENT
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VAGISTAT-1 (tioconazole) is a vaginal antifungal ointment approved in 1997 for the treatment of vulvovaginal candidiasis. It is a small-molecule azole that disrupts fungal cell membrane synthesis by inhibiting lanosterol 14α-demethylase. The product is a single-dose, over-the-counter therapy designed for rapid symptom relief in women with yeast infections.
LOE Approaching
This product is in late-stage lifecycle with approaching loss of exclusivity, signaling a transitional team focused on brand defense and generic preparation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VAGISTAT-1 offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Professionals on this team should expect focus on brand defense, cost optimization, and eventual transition to other products rather than innovation or market expansion.
Brand ManagerProduct Manager
Worked on VAGISTAT-1 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.